-+ 0.00%
-+ 0.00%
-+ 0.00%

Roth Capital Reiterates Buy on Capricor Therapeutics, Maintains $31 Price Target

Benzinga·06/17/2025 17:16:04
Listen to the news
Roth Capital analyst Boobalan Pachaiyappan reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $31 price target.